TARGET TREATMENT IN DIABETIC AND MICROVASCULAR COMPLICATIONS: AN UPDATED REVIEWAbstract
Diabetes Mellitus is the most common endocrine disorder, affecting a larger population of the world, which arises due to defective insulin secretion by beta cells in the pancreas or insulin resistance by peripheral tissues. As the disease progress, microvascular complications like nephropathy, neuropathy, retinopathy, and cardiovascular complications are observed, which the leading causes of death in diabetic patients. The drug treatment is required when the weight reduction, diet, and modification in lifestyle fails to maintain the normal blood glucose level. Though insulin and oral anti-diabetic drugs are clinically being used; the researchers have been focused on developing still better anti-diabetic drugs. There components like GLP-1, DPP-4, GPR119, GPR 40 and GPR 120, SGLT2, DGAT-1, 11 β-hydroxysteroid dehydrogenase, and Peroxisome proliferator influences/regulate the secretion, release, and uptake of insulin. The study of these targets would help to develop new anti diabetic drugs.